ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease

Mao Wei; Zhang Lei; Zou Chuan; Li Chuang; Wu Yifan; Su Guobin; Guo Xinfeng; Wu Yuchi; Lu Fuhua; Lin Qizhan; Wang Lixin; Bao Kun; Xu Peng; Zhao Daixin; Peng Yu; Liang Hui; Lu Zhaoyu; Gao Yanxiang; Jie Xina; Zhang La; Wen Zehuai*; Liu Xusheng广东省人民医院; 广州中医药大学
BMC Complementary and Alternative Medicine2015-9-8DOI: 10.1186/s12906-015-0830-1
20阅读
引用收藏
分享

摘要

Background: Chronic kidney disease (CKD) is a global public health problem. Currently, as for advanced CKD populations, medication options limited in angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), which were partially effective. A Chinese herbal compound, Bupi Yishen formula, has showed renal protective potential in experiments and retrospective studies. This study will evaluate the efficacy and safety of Bupi Yishen formula (BYF) in patients with CKD stage 4. <br>Design: In this double blind, double dummy, randomized controlled trial (RCT), there will be 554 non-diabetes stage 4 CKD patients from 16 hospitals included and randomized into two groups: Chinese medicine (CM) group or losartan group. All patients will receive basic conventional therapy. Patients in CM group will be treated with BYF daily while patients in control group will receive losartan 100 mg daily for one year. The primary outcome is the change in estimated glomerular filtration rate (eGFR) over 12 months. Secondary outcomes include the incidence of endpoint events, liver and kidney function, urinary protein creatinine ratio, cardiovascular function and quality of life. <br>Discussion: This study will be the first multi-center, double blind RCT to assess whether BYF, compared with losartan, will have beneficial effects on eGFR for non-diabetes stage 4 CKD patients. The results will help to provide evidence-based recommendations for clinicians.

相关
加载中…
  • Oral Chinese Herbal Medicine plus usual care for diabetic kidney disease: study protocol for a randomized, double-blind, placebo-controlled pilot trial
    Liu, Meifang; Di, Yuan Ming; Zhang, Lei; Yang, Lihong; Zhang, La; Chen, Junhui; Wang, Ruobing; Xie, Xiaoning; Lan, Fang; Xie, Liping; Huang, Juan; Zhang, Anthony Lin; Xue, Charlie Changli*; Liu, Xusheng*Frontiers in Endocrinology, 2024, 15: 1334609.
  • Effectiveness of Chinese herbal medicine combined with Western medicine on deferring dialysis initiation for nondialysis chronic kidney disease stage 5 patients: a multicenter prospective nonrandomized controlled study
    Wu, Yifan; Li, Chuang; Zhang, Lei; Zou, Chuan; Xu, Peng; Wen, Zehuai; Ouyang, Wenwei; Yang, Nizhi; Zhang, Min; Lin, Qizhan; Lu, Fuhua; Wang, Lixin; Bao, Kun; Zhao, Daixin; Fu, Lizhe; Guo, Xinfeng; Yang, Lihong; Ou, Aihua; He, Zehui; Weng, Heng; Li, Jianmin; Shi, Wei; Wang, Xiaoqin; Song, Liqun; Zhan, Yongli; Sun, Wei; Wei, Lianbo; Wang, Niansong; Gui, Dingkun; Zhan, Jihong; Lu, Ying; Chen, Hongyu; Liu, Yuning; Yang, Hongtao; Chen, Ming; Wang, Yiping; Zhang, Peiqing; Deng, Yueyi; Meng, LanfenAnnals of Translational Medicine, 2021, 9(6): 490.被引 3
  • Bupi Yishen formula may prevent kidney fibrosis by modulating fatty acid metabolism in renal tubules
    Liu, Bingran; Jie, Xina; Deng, Jiankun; Zhang, Simeng; Lu, Fuhua; Liu, Xusheng*; Zhang, Difei*PHYTOMEDICINE, 2023, 114: 154767.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC Complementary and Alternative Medicine
发表日期
2015-09-08
卷期
第 15 卷
页码
316
DOI
10.1186/s12906-015-0830-1
语言
ENGLISH
期刊收录
SCIE
期刊等级
Q2
成果收录
SCI
资助标注
State Administration of Traditional Chinese Medicine, P. R. China [201007005]; Research Project for Practice Development of National TCM Clinical Research Base; United Project of Guangdong Provincial Department of Science and Technology and Guangdong Provincial Academy of Chinese Medical Science [2011B032200011]

作者

  • M

    Mao Wei (第一作者)

    guangdong prov hosp

  • Z

    Zhang Lei

    guangdong prov hosp

查看全部 22 位作者收起作者
  • Z

    Zou Chuan

    guangdong prov hosp

  • L

    Li Chuang

    guangdong prov hosp

  • W

    Wu Yifan

    guangdong prov hosp

  • S

    Su Guobin

    guangdong prov hosp

  • G

    Guo Xinfeng

    guangdong prov hosp

  • W

    Wu Yuchi

    guangdong prov hosp

  • L

    Lu Fuhua

    guangdong prov hosp

  • L

    Lin Qizhan

    guangdong prov hosp

  • W

    Wang Lixin

    guangdong prov hosp

  • B

    Bao Kun

    guangdong prov hosp

  • X

    Xu Peng

    guangdong prov hosp

  • Z

    Zhao Daixin

    guangdong prov hosp

  • P

    Peng Yu

    guangdong prov hosp

  • L

    Liang Hui

    guangdong prov hosp

  • L

    Lu Zhaoyu

    guangdong prov hosp

  • G

    Gao Yanxiang

    guangdong prov hosp

  • J

    Jie Xina

    guangdong prov hosp

  • Z

    Zhang La

    guangdong prov hosp

  • W

    Wen Zehuai (通讯)

    guangzhou univ chinese med · guangdong prov hosp

  • L

    Liu Xusheng

    guangdong prov hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417